Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2009 | 1 |
2010 | 2 |
2021 | 2 |
2024 | 0 |
Search Results
5 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Social networks in cardiovascular disease management.
Expert Rev Pharmacoecon Outcomes Res. 2010 Dec;10(6):701-5. doi: 10.1586/erp.10.68.
Expert Rev Pharmacoecon Outcomes Res. 2010.
PMID: 21155703
Review.
Case for a pharmacy-centered medical home.
Shaya FT, Low S, Barakat S, Farshid M, Jung M, Norman N, Fedder DO.
Shaya FT, et al. Among authors: jung m.
Expert Rev Pharmacoecon Outcomes Res. 2009 Oct;9(5):397-9. doi: 10.1586/erm.09.27.
Expert Rev Pharmacoecon Outcomes Res. 2009.
PMID: 19817521
No abstract available.
Item in Clipboard
Prospective SPECT-CT Organ Dosimetry-Driven Radiation-Absorbed Dose Escalation Using the In-111 (111In)/Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Theranostic Pair in Patients with Lymphoma at Myeloablative Dose Levels.
Wahl RL, Frey EC, Jacene HA, Kahl BS, Piantadosi S, Bianco JA, Hammes RJ, Jung M, Kasecamp W, He B, Sgouros G, Flinn IW, Swinnen LJ.
Wahl RL, et al. Among authors: jung m.
Cancers (Basel). 2021 Jun 6;13(11):2828. doi: 10.3390/cancers13112828.
Cancers (Basel). 2021.
PMID: 34204102
Free PMC article.
Item in Clipboard
The cost effectiveness and budget impact of natalizumab for formulary inclusion.
Bakhshai J, Bleu-Lainé R, Jung M, Lim J, Reyes C, Sun L, Rochester C, Shaya FT.
Bakhshai J, et al. Among authors: jung m.
J Med Econ. 2010 Mar;13(1):63-9. doi: 10.3111/13696990903543424.
J Med Econ. 2010.
PMID: 20028199
Free article.
Item in Clipboard
An FDA Analysis of Inspected Entities After Receiving Official Action Indicated Letters for Good Clinical Practice Violations.
Jung M, Swann RM, Anantha MS, Jamali F.
Jung M, et al.
Ther Innov Regul Sci. 2021 Sep;55(5):907-917. doi: 10.1007/s43441-021-00267-y. Epub 2021 Jun 8.
Ther Innov Regul Sci. 2021.
PMID: 34101151
Free PMC article.
Item in Clipboard
Cite
Cite